DOCS Stock Recent News

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal second quarter ended September 30, 2024 after market close on November 7, 2024. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/.

NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Doximity, Inc. (NYSE: DOCS) on behalf of long-term stockholders following a class action complaint that was filed against Doximity on April 17, 2024 with a Class Period from February 9, 2022, to April 1, 2024. Our investigation concerns whether the board of directors of Doximity have breached their fiduciary duties to the company.

As of Sept. 24, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Investors interested in stocks from the Medical Services sector have probably already heard of Solventum (SOLV) and Doximity (DOCS). But which of these two companies is the best option for those looking for undervalued stocks?

Doximity recently reported strong financial results. The company has solid growth opportunities.

Investors with an interest in Medical Services stocks have likely encountered both Life Time Group Holdings, Inc. (LTH) and Doximity (DOCS). But which of these two stocks is more attractive to value investors?

Doximity reported strong Q1 FY25 earnings with revenue and Adjusted EBITDA growing 17% and 41% YoY respectively, beating estimates. It saw a 16% increase in customer count in its $500K+ Subscription revenue cohort, while usage of its products continued to grow steadily, alongside expanding margins. Although the management sounded cautious on the state of the economy, it believes that its product innovation should help it capture larger pharma budgets in the coming years.

Doximity beat estimates on the top and bottom lines. The company continues to report strong margins.

Doximity (NYSE: DOCS ) stock is rising higher on Friday following the release of the medical cloud-based digital platform company's earnings report for its fiscal first quarter of 2025. That earnings report starts off strong with adjusted EPS of 28 cents per share.

The medical platform's quarterly result beat expectations on both top and bottom lines, and is also leveraging AI to appeal to customers.